Skip to main content

Table 1 Patients and tumour characteristics

From: Evidence from a breast cancer hypofractionated schedule: late skin toxicity assessed by ultrasound

Age (years) Median 62 (31–79)
Menopausal status pre/post 25/64
pT stage  
pTis 12
pT1 66
pT2 (≤3 cm) 11
pN stage  
pN0 70
pN1 (≤ 3 positive nodes) 19
Estrogen receptor status  
Positive/negative 76/13
Progesteron receptor status  
Positive/negative 76/13
Chemotherapy yes/no 36/53
Hormonotherapy  
No 20
Tamoxifen 35
Anastrozole 18
Letrozole 16
Follow-up (months) 20.5 (11.4-85.7)